scholarly journals PCN21 SYSTEMATIC REVIEW OF COST-EFFECTIVENESS-ANALYSIS STUDIES OF TRASTUZUMAB (HERCEPTIN™) IN TREATMENT OF HER2-POSITIVE BREAST CANCER

2008 ◽  
Vol 11 (3) ◽  
pp. A60
Author(s):  
OA Le
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Effectiveness Analysis ◽  
Positive Breast Cancer

Therapie des Mammakarzinoms – Ist die zusätzliche Gabe von Pertuzumab kosteneffektiv?

2020 ◽  
Vol 25 (01) ◽  
pp. 6-6
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cost Effectiveness ◽  
Adjuvant Treatment ◽  
The United States ◽  
Cost Effectiveness Analysis ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Effectiveness Analysis ◽  
Positive Breast Cancer

Garrison L et al. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. Value Health 2019: 22(4): 408–415 Bis zu 20 % der Frauen, die von Brustkrebs betroffenen sind, zeigen eine erhöhte Konzentration des Humanen Epidermalen Wachstumsfaktor-Rezeptors 2 (HER2). HER2-positiver Brustkrebs führt im Verlauf häufig zu Rezidiven und bedarf einer zielgerichteten Therapie. Garrison et al. untersuchten in diesem Zusammenhang die Kosten-Effektivität einer zusätzlichen Gabe von Pertuzumab.

scholarly journals Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

Cancer ◽  
2007 ◽  
Vol 110 (3) ◽  
pp. 489-498 ◽  
Author(s):  
Louis P. Garrison ◽  
Deborah Lubeck ◽  
Deepa Lalla ◽  
Virginia Paton ◽  
Amylou Dueck ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Adjuvant Setting ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Effectiveness Analysis ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document